Dallas, TX (Jul. 16, 2024) – A recent survey conducted by Wondr Health, an industry leader in behavior-change programs for weight and obesity management, highlighted lifestyle change support as a top factor individuals consider when taking a weight-loss drug. While consumer demand for GLP-1 drugs remains a hot topic, these findings are especially relevant for employers as they evaluate 2025 wellness benefits that are cost-effective, deliver measurable results, and meet the diverse needs of their workforce.
Wondr Health conducted the survey in June and asked individuals to identify and multi-select which factors are most important to consider when taking weight-loss medications. 775 Wondr Health participants across 50+ employer and health plan clients responded ranking the following factors in order of importance:
- Lifestyle change support – 77.9%
- Medical supervision – 69.9%
- Overall effectiveness – 69.3%
- Potential side effects – 69.2%
- Loss of muscle tissue – 63.5%
- Cost – 57.3%
- Potential to regain weight – 54.7%
- Emotional health support – 54.5%
- FDA approval – 38.6%
- Implications for long-term use – 34.3%
“When it comes to engagement and outcomes, the findings from this survey support our published research that shows participants who consistently use the Wondr program over a 12-month period achieve clinically significant weight loss and are able to sustain it,” said Tim Church, MD, MPH, PhD, Chief Medical Officer, Wondr Health. “People will put in the work to lose weight and improve their health when they have access to lifestyle change support personalized for their individual needs.”
Regardless of where employers land on GLP-1 drug coverage, behavior change is the foundation for improving and sustaining health outcomes. Today, over 1,000 employers and 80 health plans have added the Wondr behavior-change program to benefit plans for 10 million people. In 2023, Wondr expanded its capabilities to provide clinical support, tailored medication management, and prescribing for employers who cover GLP-1s and other weight-loss drugs.
“Employers have more options than just covering GLP-1s to treat obesity,” said Scott Paddock, Chief Executive Officer, Wondr Health. “With a proven behavior-change program alone, employers will significantly improve the health of their workforce and can expect a 2.1x ROI from Wondr.”
For more information about how Wondr works for employers, visit https://wondrhealth.com/partners/employers/.
ABOUT WONDR HEALTH
Wondr Health improves access to digital, evidence-based behavioral support for full-spectrum weight and obesity management. Born in the benefits space 15+ years ago, Wondr is a clinically proven behavior-change program that treats the root cause of chronic metabolic conditions to improve quality of life and health outcomes, and prevent and reduce costs. Powered by data-driven engagement expertise and personalized programming, and supported by expert content and coaching, Wondr helps everyone achieve long-term weight loss, improve movement, reduce stress and anxiety, build healthy eating habits, get better sleep, and more. A flexible and scalable program, Wondr is the foundation with advanced clinical capabilities, including tailored prescribing and medication management, for organizations who cover weight-loss drugs. For more information, visit www.wondrhealth.com.
###
MEDIA CONTACT:
Innsena for Wondr Health
Trent Freeman
